Neutralizing antibodies against herpesvirus entry complex and fusogen

Herpesviruses lead to significant health challenges, notably through conditions like herpes, varicella, zoster, mononucleosis, and various cancers including Kaposi's sarcoma, nasopharyngeal carcinoma, and lymphoma. Yet, no approved treatments explicitly target the initial infections of herpesviruses. The herpesviruses' cell entry mechanism relies on the coordinated action of several glycoproteins and involves multiple host cell receptors. Glycoprotein B (gB) is essential for membrane fusion and gets activated by the entry complex, primarily formed of gH and gL. Given the central role of this entry complex and the fusogen in herpesvirus infections, antibodies neutralizing targeting the key epitopes on these glycoproteins offer a promising strategy to counteract herpesvirus infections.